uniQure (NASDAQ:QURE) Raised to “Strong-Buy” at Wells Fargo & Company

Wells Fargo & Company upgraded shares of uniQure (NASDAQ:QURE) from a hold rating to a strong-buy rating in a research report sent to investors on Tuesday,Zacks.com reports.

Other equities research analysts have also recently issued reports about the company. Guggenheim reissued a “buy” rating on shares of uniQure in a research note on Wednesday. Royal Bank of Canada boosted their price objective on uniQure from $14.00 to $20.00 and gave the stock an “outperform” rating in a research note on Wednesday. Cantor Fitzgerald boosted their price objective on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday. Raymond James raised uniQure from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the stock from $20.00 to $52.00 in a research note on Tuesday. Finally, StockNews.com raised uniQure to a “sell” rating in a research note on Wednesday. One research analyst has rated the stock with a sell rating, two have given a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $32.14.

uniQure Price Performance

NASDAQ:QURE opened at $15.06 on Tuesday. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The company has a market capitalization of $734.07 million, a P/E ratio of -3.04 and a beta of 0.89. uniQure has a 12 month low of $3.73 and a 12 month high of $17.39. The business’s 50-day moving average is $6.85 and its 200 day moving average is $6.28.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. The company had revenue of $2.29 million for the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. On average, equities research analysts forecast that uniQure will post -3.74 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the transaction, the chief executive officer now owns 597,915 shares of the company’s stock, valued at $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.74% of the stock is owned by insiders.

Institutional Trading of uniQure

A number of hedge funds have recently bought and sold shares of QURE. Vanguard Group Inc. lifted its holdings in uniQure by 11.4% during the first quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock worth $5,577,000 after buying an additional 109,740 shares during the period. SG Americas Securities LLC purchased a new stake in shares of uniQure during the 2nd quarter valued at $79,000. Assenagon Asset Management S.A. purchased a new stake in shares of uniQure during the 2nd quarter valued at $815,000. Privium Fund Management B.V. lifted its holdings in shares of uniQure by 10.6% during the 2nd quarter. Privium Fund Management B.V. now owns 640,416 shares of the biotechnology company’s stock valued at $2,869,000 after purchasing an additional 61,501 shares during the last quarter. Finally, Doheny Asset Management CA purchased a new stake in shares of uniQure during the 2nd quarter valued at $1,220,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.